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Reactive nitrogen speciesdeﬁciency induces hyperhomocysteinemiawhich is considered as a risk factor for
vascular diseases. Studies underlined the importance of altered cellular redox reactions in hyperhomocystei-
nemia-induced vascular pathologies. Nevertheless, hyperhomocysteinemia also induces hepatic dysfunction
whichmay accelerate the development of vascular pathologies bymodifying cholesterol homeostasis. The aim
of the present study was to analyze the modiﬁcations of redox state in the liver of heterozygous cystathionine
beta synthase-deﬁcient mice, a murine model of hyperhomocysteinemia. In this purpose, we quantiﬁed levels
of reactive oxygen and nitrogen species and we assayed activities of main antioxidant enzymes. We found that
cystathionine beta synthase deﬁciency induced NADPH oxidase activation. However, there was no
accumulation of reactive oxygen (superoxide anion, hydrogen peroxide) and nitrogen (nitrite, peroxynitrite)
species. On the contrary, hepatic hydrogen peroxide level was decreased independently of an activation of
glutathione-dependent mechanisms. In fact, cystathionine beta synthase deﬁciency had no effect on
glutathione peroxidase, glutathione reductase and glutathione S-transferase activities. However, we found a
50% increase in hepatic catalase activity without any variation of expression. These ﬁndings demonstrate that
cystathionine beta synthase deﬁciency initiates redox disequilibrium in the liver. However, the activation of
catalase attenuates oxidative impairments.
© 2008 Elsevier B.V. All rights reserved.1. Introduction
Homocysteine (Hcy) is a thiol-containing amino acid at the
crossroad of the methionine metabolism (Fig. 1). Dietary methionine
is adenosylated by methionine adenosyl transferase to form S-
adenosyl methionine, the universal methyl donor. Once formed via
the demethylation pathway, Hcy may undergo remethylation to form
methionine via folate- or betaine-dependent mechanisms. Otherwise,
Hcy may enter the transsulfuration pathway leading to the formation
of cysteine and then glutathione (GSH), the major cellular antioxidant.
GSH is used by glutathione peroxidase (GPx) to detoxify hydrogen
peroxide (H2O2) and oxidized glutathione (GSSG) is subsequently
regenerated to GSH by glutathione reductase (GRed). GSH also serves
as a substrate for glutathione S-transferase (GST) in the detoxiﬁcation
of xenobiotics or endogenous compounds such as lipid peroxides.
Abnormally high plasma Hcy levels are characteristic of hyperho-
mocysteinemia, a metabolic disease which can be due to alteredrot – Paris 7, Case 7104, 75205
1 44 27 83 38.
).
ll rights reserved.genetic or nutritional factors involved in Hcy metabolism [1]. Three
different types of hyperhomocysteinemia were identiﬁed depending
on Hcy concentration: moderate (15–30 µM), intermediate (30–
100 µM) and severe (N100 µM) [2]. Necropsies of severe hyperhomo-
cysteinemic patients notably revealed atherosclerosis, thrombosis and
hepatic steatosis [3,4]. Moreover, even a moderate elevation of total
Hcy level is recognized as an independent vascular risk factor for
atherothrombosis in the coronary, cerebrovascular and peripheral
arterial circulation [5–8].
Several studies reported impaired endothelial functionality and
antithrombotic mechanisms [9]. In vivo studies supported by in vitro
results imputed notably the impairment of endothelial vasomotor
function to Hcy-induced reduced NO bioavailability [10,11]. Even if
vascular toxicity of Hcy is indisputable, the hepatic dysfunction might
play a key role in the development of vascular diseases. In this sense,
Hcy metabolism is mainly hepatic [12] and liver damage promotes
hyperhomocysteinemia through cystathionine beta synthase (CBS),
betaine homocysteine methyl transferase and methionine synthase
downregulation [13]. Furthermore, several vascular atherogenic
factors arise from hepatic dysfunction induced by hyperhomocystei-
nemia [14–18]. In vitro studies have shown that cellular damage
induced by Hcy was linked to oxidative stress [19,20] and GPx-1
Fig. 1. Integrated pathways for homocysteine and glutathione synthesis frommethionine. DHF, dihydrofolate; DHFR, dihydrofolate reductase; THF, tetrahydrofolate reductase; STHM,
serine transhydroxymethylase; CH2THF, 5,10-methylene tetrahydrofolate; MTHFR, 5,10-methylene tetrahydrofolate reductase; CH3THF, 5-methyl tetrahydrofolate; MS, methionine
synthase; BHMT, betaine homocysteine methyl transferase; DMG, N,N-dimethyl glycine; MAT, methionine adenosyl transferase; SAM, S-adenosyl methionine; SAH, S-adenosyl
homocysteine; SAHH, S-adenosyl homocysteine hydrolase; CBS, cystathionine beta synthase; CGL, cystathionine gamma lyase; γGCS, γ-glutamyl cysteine synthase; GS, glutathione
synthetase; GPx, glutathione peroxidase; GSSG, oxidized glutathione; NADPH, reduced nicotinamide adenine dinucleotide phosphate; G6PD, glucose 6-phosphate dehydrogenase;
NADP, oxidized nicotinamide adenine dinucleotide phosphate; GRed, glutathione reductase.
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[21]. Hcy is thought to induce reactive oxygen species (ROS) accu-
mulation either by direct ROS generation via auto-oxidation [22] or by
disturbing the balance between prooxidant and antioxidant activities.
Such a disequilibrium between ROS producing and detoxifying
enzymatic activities arises primarily from an increased production
of superoxide anion (O2
U−), the univalent reduction of dioxygen, by
mitochondrial respiratory complexes or various oxidases such as
nicotinamide adenine dinucleotide phosphate (NADPH) oxidase and
xanthine oxidase. O2
U− can react with nitric oxide (NO) to form
peroxynitrite (ONOO−), a DNA and protein damaging agent. Thus an
increase in O2
U− production can decrease NO bioavailability. Therefore
O2
U− is rapidly dismutated into H2O2 by superoxide dismutase (SOD).
However, H2O2 itself is a cytotoxic oxygen radical and leads through
the Fenton's reaction to the formation of the highly reactive hydroxyl
radical (HO˙). Thus H2O2 is degraded to H2O and O2 by catalase (CAT)
and GPx.
Experimental hyperhomocysteinemia can be obtained by dietary
interventions such as vitamin B6, B12, and folate deﬁciency or methio-
nine supplementation, or by genetic approaches such as CBS [23],methylene tetrahydrofolate reductase [24] and methionine synthase
[25] deﬁciency. Some of these hyperhomocysteinemic models have
notably been used to elicit Hcy inﬂuence on main hepatic antioxidant
activities [26–31]. However, the inﬂuence of CBS deﬁciency on hepatic
redox state has never been extensively studied. Heterozygous CBS-
deﬁcient mice show hepatic gene expression modulation of several
cytochromes, indicating perturbation of the hepatic redox potential
[32]. Therefore, we characterized the hepatic redox state in CBS-
deﬁcient mice by quantiﬁcation of ROS, reactive nitrogen species (RNS)
and activities of the main enzymes involved in redox homeostasis.
2. Materials and methods
2.1. Chemicals and antibodies
Unless mentioned otherwise all chemicals and antibodies were obtained from
Sigma (Sigma-Aldrich, Saint Quentin Fallavier, France).
2.2. Mice
Animal care was conducted in accordance with internal guidelines of the French
Ministère de l'Agriculture for animal handling.Mice heterozygous for targeted disruption
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Pathology, University of North Carolina, Chapel Hill, NC, USA). Cbs +/−mice, on a C57BL/6
background, and their wild-type C57BL/6 littermates (Cbs +/+) were used. Cbs +/− mice
were produced bymatingmale Cbs +/−micewith female Cbs +/+mice. Tail biopsies were
performed on mice at 4 weeks of age and polymerase chain reaction was used for
genotyping as previously described [23]. Mice were fed a standard laboratory diet (A03,
Safe, Augy, France) given ad libitum. This diet has an approximativeprotein contentof 21%,
amethionine content of 4.8 g kg− 1, a folic acid content of 0.9mg kg− 1 andavitaminB6 and
B12 content of respectively 3.5 and 0.04 mg kg− 1.
2.3. Preparation of samples and plasma total Hcy assay
At time of sacriﬁce, blood sampleswere collected into tubes containing1/10 volumeof
3.8% sodium citrate and placed on ice immediately. Plasmawas isolated by centrifugation
at 2500g for 15 min at 4 °C. Plasma total Hcy was assayed by using the ﬂuorimetric high-
performance liquid chromatography method described by Fortin and Genest [33]. Livers
were harvested, snap-frozen and stored at − 80 °C until use. 100 mg of liver were
homogenized in 500 µL Dulbecco's phosphate-buffered saline (Invitrogen, Cergy, France)
containing proteases inhibitors. Homogenates were centrifuged at 13000g for 15 min at
4 °C. Supernatants were then assayed for protein concentrations by the Bradford assay.
2.4. RNA extraction and determination of mRNA levels
RNA were prepared from liver with the NucleoSpin RNA II kit (Macherey Nagel,
Hoerdt, France). Quantity and purity of the RNAwere assessed by measuring absorbance
at 260 and 280 nm. Reverse transcriptionwas carried out on 1 µg RNA as described by the
manufacturer (Applied Biosystems, Courtaboeuf, France). Catalase and heme oxygenase 1
(HO-1) mRNA levels were analyzed by real-time quantitative reverse transcription-
polymerase chain reaction as previously described [18] using the Light Cycler FastStart
DNA Master SYBR Green I Kit (Roche Diagnostics, Meylan, France). Primers (Eurogentec
SA, Seraing, Belgium; Table 1) were designed with the Primer3 software [34] to yield a
single amplicon based on dissociation curves. Each reaction was performed in duplicate.
Themouse superoxidedismutase-1mRNAwasused as an endogenous control [32].ΔΔCp
analysis of results allows to assess the ratio of the target mRNAversus controlmRNA [35].
2.5. Western blot analysis
60 µg of total proteins was subjected to SDS electrophoresis on 12% acrylamide gels
under reducing conditions and transferred to Hybond-C Extra membrane (GE
Healthcare Europe GmbH, Saclay, France). After transfer, membranes were blocked in
10% nonfat dry milk in Tris-saline buffer (1.5 mM Tris, 5 mM NaCl, 0.1% Tween 20) and
probed with anti-heme oxygenase 1 (HO-1) antibody (Calbiochem, San Diego, USA).
Horseradish peroxidase-conjugated secondary antibody and Western Blotting Luminol
Reagent (Santa Cruz Biotechnology, Heidelberg, Germany) were used to detect speciﬁc
proteins. β-actin was used as internal control.
2.6. Measurement of NADPH oxidase activity
NADPH oxidase activity was measured by monitoring the oxidation rate of
cytochrome c as described by Iwai et al. [36] with 20 µg of total proteins. NADPH oxidase
activity was quantiﬁed from the absorbances at 540, 550 and 560 nm as previously
described [37].
2.7. Determination of superoxide anion content
O2
U− levelswere determined on 300 µg of total proteins after hemoglobinprecipitation
bymonitoring the oxidation of dihydroethidium into ethidium as described byWoo et al.
[26].
2.8. Measurement of SOD activity
SOD activity was measured with 20 µg of total proteins by using the Superoxide
Dismutase Kit (R&D Systems Europe, Lille, France) following the supplier's instructions.
Measurement of enzyme activity is based on the competition of SOD and nitroblue-
tetrazolium for O2
U−.Table 1
Primer sequences for real-time quantitative reverse transcription-polymerase chain
reaction
Gene Left primer Right primer
Cat CCTCCTCGTTCAGGATGTGGTT CGAGGGTCACGAACTGTGTCAG
Ho-1 GCAGGTGATGCTGACAGAGGAA GGGGGCCAGTATTGCATTTACA
Sod-1 TGGGGACAATACACAAGGCTGT TTTCCACCTTTGCCCAAGTCA
All primers are listed 5′ to 3′. Cat: catalase, Ho-1: heme oxygenase-1, Sod-1: superoxide
dismutase-1.2.9. Determination of hydrogen peroxide content
H2O2 was quantiﬁed on 100 µg of proteins, after hemoglobin precipitation, with the
Amplex Red Hydrogen Peroxide/Peroxidase Assay Kit (Invitrogen, Cergy, France) as
recommended by the supplier's instructions. Measurement of H2O2 level is based on the
production of resofurin by H2O2 and Amplex Red reagent in the presence of peroxidase.
2.10. Determination of nitrites and nitrates contents
Nitrite and nitrate levels were determined by Marzinzig et al. modiﬁed Griess
reaction [38]. 8mgof total proteinwas deproteinized byacetonitrile–chloroformprotein
precipitation [39]. To reduce nitrates into nitrites 400 µL of deproteinized sample was
incubated in the dark for 1h at 37 °C with 20 µL FAD 200 µM, 20 µL NADPH 6 mM and
10 µL nitrate reductase 5 U/mL. Then excess NADPH was oxidized with 20 mM sodium
pyruvate and 0.5U L-lactate dehydrogenase in aﬁnal volumeof 500 µL. Total nitrite levels
(representing nitrites and nitrates) were spectrophotometrically determined at 550 nm
after 5 min incubation with not premixed 250 µL ice-cold dapsone (4,4'-diamino-
diphenylsulfone; 14 mM in 2N HCl) and 250 µL 4 mM N-(1-naphtyl)-ethylendiamine.
2.11. Determination of peroxynitrite content
ONOO− levels were measured by assaying ONOO– mediated nitration of phenol
with 200 µg of total proteins as described by VanUffelen et al. [40].
2.12. Measurement of catalase activity
CATactivitywasmeasured on liver extract corresponding to 25 µg of total proteins in
1.5 mL of 50 mM Tris buffer pH 7.8, containing 2 mM MgCl2 and 2 mM CaCl2.The
maximum CAT activity was determined with a sensitive Clark electrode measuring
dioxygenproducedby thedismutationofH2O2. 2–8µLH2O2 (100mM)wereprogressively
injected, in order to obtain the maximum production rate of dioxygen.
2.13. Measurement of glutathione peroxidase activity
GPx activity was measured by the modiﬁed Paglia and Valentine method [41]
described by Carmagnol et al. [42]. Hemoglobin was ﬁrst converted to cyanmethe-
moglobin to avoid interference. Total proteins were incubated at 30 °C in 1mL of 0.1 M
potassium phosphate buffer with 1 mM glutathione, 1 mM tert-butyl hydroperoxide,
1.4U of GRed (Type III), 1.43 mM NADPH and 1.5 mM KCN. GSSG produced by GPx and
hydroperoxide was reduced by NADPH and GRed. Then NADPH oxidation was followed
spectrophotometrically at 340 nm.
2.14. Measurement of glutathione reductase activity
GRed activity was measured by spectrophotometrically monitoring NADPH
oxidation at 340 nm as described by Carlberg and Mannervik [43]. Total proteins
were incubated at 30°C in 1mL of 0.1 M potassium phosphate buffer with 2 mMNADPH
and 20 mM glutathione disulﬁde.
2.15. Measurement of glutathione S-transferase activity
GST activity was assayed by the method described by Habig et al. [44]. S-conjugate
formation was followed at 25 °C, pH 6.5 in a 0.1 M phosphate potassium buffer with
1 mM GSH and 1 mM 1-chloro-2,4-dinitrobenzene by monitoring changes in
absorbance at 340 nm.
2.16. Statistical analysis
Results are expressed as mean±SEM. Statistical analysis was done with Mann–
Whitney–Wilcoxon's test using R software (http://www.R-project.org). Data were
considered signiﬁcant when p ≤ 0.05.
3. Results
3.1. Plasma Hcy levels in CBS-deﬁcient mice
In order to characterize the effects of CBS deﬁciency on hepatic
redox status, we used male Cbs +/− mice and male Cbs +/+ from the
same litter aged from 6 to 10 months. As expected, heterozygous CBS-
deﬁcient mice displayed abnormal plasma Hcy levels compared to
wild-type mice (8.9±0.8 µM, n = 10 vs. 3.9±0.3 µM, n = 8; p b 0.0001).
3.2. HO-1 expression in the liver of CBS-deﬁcient mice
Induction of HO-1 expression is recognized as amarker of oxidative
stress [45]. Therefore, the hepatic expression of HO-1 was analyzed to
determine if the rise of Hcy induced by heterozygous CBS deﬁciency
Fig. 3. Production and concentration of O2˙− and H2O2 in the liver of Cbs +/+ and Cbs +/−
mice. Activities and concentrations are presented as mean percentages±SEM of mean
values of n (number of mice) Cbs +/+ mice. ⁎pb0.05.
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of HO-1 mRNA in the liver of Cbs +/− mice (100.0±6.0% vs. 146.4±
15.2%; p = 0.015, Fig. 2A). In agreement with increased levels of HO-1
mRNA, albeit the difference was not signiﬁcant, HO-1 protein expres-
sion appeared to be increased (100.0±26.7%, n = 4 vs. 159.0±24.1%, n =
4; p b 0.1, Fig. 2B).
3.3. Effect of CBS deﬁciency on hepatic ROS production
Even thoughNADPHoxidase activitywas increased in liver of Cbs +/−
mice (100.0±2.0% vs. 109.6±2.5%, p = 0.04, Fig. 3A), there was no
increase in O2
U− level. On the contrary, we observed a non signiﬁcant
decreased concentration of O2
U− (100.0±10.1% vs. 81.1±5.6%, p = 0.28,
Fig. 3B). The regulation of hepatic level of O2
U− could be due to an
activation of SOD. However, we only observed a non signiﬁcant increase
in SOD activity (100.0±7.8% vs. 113.1±7.1%, p = 0.48, Fig. 3C) and
surprisingly, we found a signiﬁcant decrease in H2O2 level in liver of
Cbs +/−mice compared to Cbs +/+ mice (100.0±5.2% vs. 75.8±10.3%, p=
0.04, Fig. 3D).
3.4. Effect of CBS deﬁciency on hepatic RNS production
Reduced NO bioavailability is a key process in Hcy-induced vascular
pathology but the implication of NO in liver diseases remains unclear
[46]. We measured nitrite and nitrate levels as being representative of
NO release.Measurement of nitrites alone didnot give detectable signal
indicating that, in the liver, nitrates are the main NO derivatives. After
nitrate reduction into nitrites we did not observed any signiﬁcant
difference between hepatic concentrations of Cbs +/− and Cbs +/+ mice
(100.0±4.8% vs. 104.0±8.5%, p = 0.80, Fig. 4A). The reaction of O2
U− with
NO leads to the formation of ONOO−. As we have observed an increased
production of O2
U− by NADPH oxidase but no accumulation of O2
U−, this
could be due to an immediate reactivity of O2
U−with NO. However, there
was no increase in ONOO− generation (100.0±12.6% vs. 91.5±7.7%, p =
0.70, Fig. 4B) in liver of Cbs +/−mice compared to Cbs +/+ mice.Fig. 2. Effect of CBS genotype onHO-1 expression. HO-1mRNA levels (A)were quantiﬁed
by real-time quantitative reverse transcription-polymerase chain reaction. Expression
levels are presented as mean percentages±SEM of mean values of n (number of mice)
Cbs +/+ mice. Effect of CBS genotype on HO-1 protein levels has been determined by
Western blotting (B). The presented blot speciﬁc for HO-1 and β-actin, as a loading
control, is representative of 3 experiments with 4 mice in each group. ⁎pb0.05.3.5. Effect of CBS deﬁciency on hydrogen peroxide detoxiﬁcation
As we have observed a decreased H2O2 hepatic content, we
investigated by which mechanism this ROS was detoxiﬁed. GPx is able
to detoxify H2O2 by oxidizing GSH, the main cellular antioxidant
compound. Sowe assayed GPx and GRed to determine if the decrease in
H2O2 could be due to an activation of the GSH-dependent detoxiﬁcation
cycle. Both GPx (100.0±4.3% vs. 105.7±5.1%, p = 0.37, Fig. 5A) and GRed
(100.0±3.0% vs. 103.9±4.2%, p=0.50, Fig. 5B) activities remained un-
changed in liver of Cbs±mice compared to Cbs +/+mice.We also assayed
hepatic GST activity (100.0±6.8% vs. 95.4±12.5%, p=0.74, Fig. 5C) and
found no variation. The liver is rich in CAT, a major enzyme involved in
H2O2 detoxiﬁcation. Then, we investigated if the decrease in hepatic
H2O2 level could be due to CAT activation. Indeed, we found a 1.5−fold
increase in CAT activity in liver of Cbs +/p mice compared to Cbs +/+Fig. 4. Effect of CBS deﬁciency on RNS hepatic content. Concentrations are presented as
mean percentages±SEM of mean concentration of n (number of mice) Cbs +/+ mice.
Nitrites were quantiﬁed after nitrate reduction.
Fig. 5. Activities of hydrogen peroxide detoxiﬁcation enzymes in the liver of Cbs +/+ and
Cbs +/− mice. GPx, GRed, GST and CAT activities are presented as mean percentages
±SEM of mean activities of n (number of mice) Cbs +/+ mice. ⁎pb0.05.
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the expression of CAT to determine if the increase in activity was due to
an overexpression. However, we did not found any variation of CAT
mRNA expression between wild-type mice and our hyperhomocystei-
nemic model (100.0±6.0% vs. 98.4±7.4%, p=0.68), indicating that it is
not a regulation of catalase activity at the molecular level.
4. Discussion
A moderate increase in Hcy level is considered as a risk factor for
vascular diseases [5–8]. As in vitro studies demonstrated that Hcy
leads to both increased ROS production and decreased antioxidant
defenses [19,20,47], numerous studies focused on the vascular redox
state of animal models. Hepatic metabolism also has a preponderant
role on vascular function by regulating circulating cholesterol home-
ostasis [14–18]. However, only a limited number of studies character-
ized the hepatic redox state in case of hyperhomocysteinemia. Then
we quantiﬁed hepatic levels of ROS and RNS and assayed activities of
the main antioxidant enzymes in the liver of Cbs +/- mice.
Wedecided tousea geneticmodel rather thananutritionalmodel to
avoid Hcy-independent side effects induced by dietary modiﬁcations.
Among nutrional approaches folate depletion and methionine enrich-
ment are the most commonly used. Dietary models may be directly
relevant to studygeneral consequences of hyperhomocysteinemia since
nutritional factors are the primary cause of Hcy accumulation in
humans. However, as folates are important cofactors in 1-carbon
metabolism, folate deﬁciency can lead to hypomethylation. Further-
more, Symons et al. [48], reported that folate depletion induced
endothelial cell layer permeability independently of hyperhomocystei-
nemia. Similarly, Troen et al. [49] demonstrated that a high-methionine
diet induces vascular symptoms that are more strongly linked to the
methionine load than to an Hcy accumulation in ApoE−deﬁcient mice.
On the other hand, homozygous CBS deﬁciency induces a decrease inGSH level [50] resulting from the complete blockade of the transsul-
furation pathway. Hence, the redox state of Cbs −/− mice might be
strongly inﬂuenced by GSH depletion. Therefore, we used Cbs +/- mice,
an intermediate model in which Hcy-independent perturbations are
minimal, to study the mechanisms of hepatic Hcy toxicity.
Concomitant with overexpression of HO−1, we found an increase in
NADPHoxidase activity in the liver of Cbs +/-mice,which is in linewith
the results of Woo et al. in the liver of mice fed a high−methionine diet
[26]. NADPH oxidase activation is the key step in the development of
oxidative stress via an accumulation of O2
U−. However, there was no
accumulation of O2
U− in the liver of Cbs +/− mice compared to Cbs +/+
mice. Moreover, we did not found any accumulation in plasma (data
not shown)which is consistentwith the results obtained byDayal et al.
in carotid artery of Cbs +/- mice [51]. Previous results showed that
induction of HO-1 suppressed NADPH-oxidase-derived oxidative
stress in hyperlipidemic apolipoprotein (E)−deﬁcient mice [52].
O2
U− also reacts rapidly with biological molecules. Then the modest
increase in O2
U− production throughNADPH oxidase activationmight be
quenched by an immediate reactivity of O2
U–with lipids, proteins, NO or
to an increase in SOD activity. Previous studies associated increased
oxidation of lipids and/or proteins with hyperhomocysteinemia due to
whether CBS deﬁciency [53], methionine supplementation [27-28] or
folate depletion [30].
To assess the role of Hcy−induced hepatic physiopathology on NO
bioavailability, we quantiﬁed RNS. As a measure of NO production we
quantiﬁed nitrites after nitrate reduction in liver homogenates and
found no difference between Cbs +/+ and Cbs +/−mice. Once produced
by NO synthase, NO can react with O2
U− to form ONOO− which can
notably damage proteins and DNA. We then quantiﬁed ONOO− in the
liver of Cbs +/−mice but found no difference compared to Cbs +/+mice.
Moreover, as it has been described in folate deﬁciency [30] and
methionine supplementation [28] there was no activation of SOD in
the liver of Cbs +/− mice. The dismutation of O2
U− by SOD results in the
formation of H2O2, a less cytotoxic ROS but which can lead to the
formation of the highly reactive hydroxyl radical. Against all expecta-
tions,we found a 25% decrease inH2O2 hepatic concentration in Cbs +/−
mice compared to their Cbs +/+ littermates.We then investigatedwhich
antioxidant process could account for such a decrease.
Activities of GPx, GRed and GST in the liver of Cbs +/- mice were
similar to those observed in Cbs +/+ mice. These results indicate that
GSH-dependent detoxiﬁcation of H2O2 or oxidized lipids is not activated
by Hcy. This ﬁnding is in agreement with the independence of hepatic
GSH concentration and heterozygous CBS deﬁciency previously
reported by Likogianni et al. [54]. Nevertheless, this is discrepant with
previous results obtained with murine models of hyperhomocysteine-
mia. In heterozygous CBS-deﬁcient mice, Weiss et al. reported a 14%
decrease in GPx-1 activity [31]. This differencemight arise from the fact
that there is a 6.5-fold factor between the folate contents of our diets. In
the cell, GPxcontribution toH2O2 detoxiﬁcation ismuch less than thatof
CAT [55]. Then,we analyzed CATactivity and found a 1.5−fold increase in
the liver of Cbs +/−mice compared to Cbs +/+ mice. This increase could
explain the decrease in H2O2 hepatic content in Cbs +/−mice. We found
that the increase in CAT activity was not due to an overexpression. It is
known that CATactivity is regulated viamodulationof phosphorylations
[56]. In this sense, we showed the activation of protein kinase A (PKA)
signalling pathways in an ex vivomodel of hippocampal slices incubated
with Hcy [57]. Moreover, Woo et al. also demonstrated in hepatocytes
the involvement of PKA signalling pathway in hyperhomocysteinemia
[58]. Thus, the activation of PKA by Hcy in hepatocytes could explain the
observed increase in CAT activity. Previous studies with dietary
approaches observed either a decrease [26,27] or no difference [28–30]
of CATactivity in the liver of Cbs +/-mice compared to Cbs +/+mice. Such
heterogeneity could arise from the fact thatdifferent animalmodels have
been used. For instance, a limitation to some studies is that methionine-
enriched diet increases GSH levels in wild-type mice which could
interfere with Hcy-induced oxidative stress [54].
487J. Hamelet et al. / Biochimica et Biophysica Acta 1782 (2008) 482–488Our results showed that therewasnoaccumulationofROSandRNS in
the liver of CBS-deﬁcient mice despite an activation of NADPH oxidase.
This ability of the liver tomaintain its redox balance seems to be due to a
signiﬁcant increase in CAT activity. In aorta of the same model of
hyperhomocysteinemia evoked by CBS deﬁciency, Eberhardt et al. [11]
reported an increased staining for 3-nitrotyrosine, a marker of
peroxynitrite formation, on the endothelial surface. Furthermore, they
observed a trend to enhance lipid peroxidation in serum but not in the
liver of CBS-deﬁcientmice. Taken together, their andourﬁndings suggest
thatHcy ismore deleterious for the vessels than for the liver. This hepatic
strength might be due to better antioxidant defenses, as CAT activity is
about 10-fold higher in the liver than in the aorta [59,60]. Furthermore,
we previously demonstrated that Hcy is intracellular in hepatocytes
whereas it is not detected in vascular endothelial and vascular smooth
muscle cells [61]. Hence, Hcy toxicity could implicate different pathways
depending on whether Hcy is intracellular or extracellular.
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